Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Advanced or Metastatic CRC
Interventions
DRUG

Hydroxytyrosol

"Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression.~The prescribed FOLFIRI/FOLFOX administer as: Irinotecan 180 mg/m² intravenously (IV) over 90 minutes concurrently with Leucovorin 400 mg/m² IV over 120 minutes, followed by Fluorouracil 400-500 mg/m² IV bolus then 2400-3000 mg/m² IV infusion over 4-6 hours with or without, the designated Biologics, a standard dose of Cetuximab or Bevacizumab will be administered in 2-week cycles until disease progression or un-tolerated toxicity"

Trial Locations (1)

77030

RECRUITING

Houston Methodist., Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER